Stock fundamentals · FY2025 · SEC 10-K data

Citigroup Inc (C) stock fundamentals

Citigroup Inc (C) reported $85.2B in revenue and $14.3B in net income in fiscal 2025, including a $3.0M loss from discontinued operations; its net margin on continuing operations was 16.8%, per its latest SEC 10-K filing. It carries a market capitalization of about $224.5B at a delayed share price. It scores 39/100 on WealthyBud's Investor Score, ranking #83 of 103 covered companies. Score is research, not investment advice.

Revenue (FY2025)
$85.2B
▲ +5.6% YoY
Net income
$14.3B
16.8% net margin on continuing operations
Market cap
$224.5B
Price $128.32 · delayed
P/E ratio
15.7
Price / earnings
Return on equity
7%
Net income / equity
Investor Score
39/100
#83 of 103 covered

Citigroup Inc fundamentals at a glance

The table summarizes Citigroup Inc's key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.

Citigroup Inc (C) fundamentals — FY2025, from SEC 10-K
MetricValueDetail
Revenue$85.2B+5.6% YoY
Net income$14.3B16.8% margin on continuing operations
Income from continuing operations$14.3BNet income including a $3.0M loss from discontinued operations; basis for net margin and P/E
Gross marginn/aNo gross profit line in the SEC data
Operating marginn/aNo operating income line in the SEC data
Return on equity7%Net income / equity
Return on assets1%Net income / assets
Revenue growth (YoY)+5.6%FY2024 to FY2025
Revenue 3-yr CAGR+4.2%Compound annual
Diluted EPS$6.99FY2025
Debt-to-equity1.49Long-term debt incl. current portion / equity
Current ration/aNot reported: no current assets / liabilities split
Cash & equivalents$349.6BBalance sheet
Total assets$2.66TFY2025 year-end
Shareholders’ equity$212.3BFY2025 year-end
Share price$128.32Delayed · 2026-10-02
Market cap$224.5BPrice × shares outstanding
P/E ratio15.7Market cap / income from continuing operations
P/S ratio2.6Market cap / revenue
Dividend yield1.81%Dividend / price

How profitable is Citigroup Inc?

Citigroup Inc posted a 16.8% net margin on continuing operations in fiscal 2025, turning $85.2B of revenue into $14.3B of income from continuing operations. Its return on equity was 7% and its return on assets 1%.

Is Citigroup Inc growing?

Citigroup Inc's revenue changed +5.6% in fiscal 2025 and compounded at +4.2% a year over three years, reaching $85.2B. Diluted earnings per share were $6.99 for the year.

Citigroup Inc annual revenue, 2021–2025
Fiscal yearRevenueGrowth
2021$71.9BFirst year shown
2022$75.3B+4.8%
2023$78.1B+3.6%
2024$80.7B+3.4%
2025$85.2B+5.6%

How is Citigroup Inc valued?

Citigroup Inc carries a market capitalization of $224.5B at a delayed share price of $128.32. It trades at 15.7 times continuing-operations earnings and 2.6 times sales. Its dividend yield is 1.81%. Its Value subscore is 70/100 across the covered universe.

How financially healthy is Citigroup Inc?

Citigroup Inc ended fiscal 2025 with $349.6B in cash, a debt-to-equity ratio of 1.49 and a current ratio that is not reported because the balance sheet does not split current assets and liabilities. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.

What is Citigroup Inc's Investor Score?

Citigroup Inc scores 39/100 on WealthyBud's Investor Score, #83 of 103 covered companies as of 2026-10-02. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.

Investor Score
39/100
#83 of 103 covered companies
Growth
47
Profitability
49
Returns on capital
4
Balance-sheet strength
23
Value (valuation)
70

Subscores are percentile ranks (0–100) across the 103 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.

Citigroup Inc (C) stock FAQ

How much revenue does Citigroup Inc make?
Citigroup Inc (C) reported $85.2B in revenue in fiscal 2025, +5.6% versus the prior year, according to its SEC 10-K filing. Its revenue compounded at +4.2% a year over three years.
Is Citigroup Inc profitable?
Yes. Citigroup Inc reported $14.3B of net income in fiscal 2025, including a $3.0M loss from discontinued operations. Income from continuing operations was $14.3B, a 16.8% net margin. Its return on equity was 7% and its return on assets 1%. These figures come from its latest 10-K.
How fast is Citigroup Inc growing?
Citigroup Inc's revenue changed +5.6% year over year in fiscal 2025 and compounded at +4.2% a year over three years. Growth is one of five inputs to its WealthyBud Investor Score, scored 47/100 versus the covered universe.
What is Citigroup Inc's market cap and P/E ratio?
Citigroup Inc has a market capitalization of $224.5B at a delayed share price of $128.32. It trades at 15.7 times continuing-operations earnings and 2.6 times sales. Its dividend yield is 1.81%. Prices are delayed and illustrative.
What is Citigroup Inc's WealthyBud Investor Score?
Citigroup Inc scores 39/100, ranking #83 of 103 covered companies as of 2026-10-02. The score is a percentile blend of growth (47), profitability (49), returns on capital (4), balance-sheet strength (23) and value (70). It is a research opinion, not investment advice.
Where does this Citigroup Inc financial data come from?
Fundamentals come from Citigroup Inc's annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from Citigroup Inc’s FY2025 Form 10-K filed with the SEC (EDGAR, public domain), retrieved 2026-10-02. Share price is a delayed end-of-day quote; market cap, P/E, P/S and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion. Not investment advice.

More large-cap stocks

Darius Okafor Healthcare Sector Analyst

Darius Okafor is a healthcare sector analyst who covers pharmaceutical, biotech and healthcare-services equities, focusing on revenue durability and margin trends. He builds his coverage from public SEC filings and FDA disclosures.

Editorial persona: WealthyBud bylines are editorial personas, not real individuals. Pages are produced by the WealthyBud research team from the public data cited on each page.